Adrian F Hernandez, Jacob A Udell, W Schuyler Jones, Stefan D Anker, Mark C Petrie, Josephine Harrington, Michaela Mattheus, Svenja Seide, Isabella Zwiener, Offer Amir, M Cecilia Bahit, Johann Bauersachs, Antoni Bayes-Genis, Yundai Chen, Vijay K Chopra, Gemma Figtree, Junbo Ge, Shaun Goodman, Nina Gotcheva, Shinya Goto, Tomasz Gasior, Waheed Jamal, James L Januzzi, Myung Ho Jeong, Yuri Lopatin, Renato D Lopes, Béla Merkely, Puja B Parikh, Alexander Parkhomenko, Piotr Ponikowski, Xavier Rossello, Morten Schou, Dragan Simic, Philippe Gabriel Steg, Joanna Szachniewicz, Peter van der Meer, Dragos Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L Bhatt, Javed Butler
BACKGROUND: Empagliflozin reduces the risk of heart failure events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, and in those with prevalent heart failure irrespective of ejection fraction. While EMPACT-MI showed empagliflozin does not reduce the risk of the composite of hospitalization of heart failure and all-cause mortality, the impact of empagliflozin on first and recurrent heart failure events in patients after myocardial infarction is unknown...
April 6, 2024: Circulation